Abstract: This disclosure relates to hybrid antigen binding molecules including at least two polypeptide chains, with at least one polypeptide chain comprises an antigen binding moiety linked to an amino acid sequence of a subunit of a heterodimeric proteinaceous hormone. Also disclosed are methods of making and using such hybrid antigen binding molecules for diagnosis and/or therapy.
Type:
Grant
Filed:
November 21, 2006
Date of Patent:
October 26, 2010
Assignee:
Merck Serono, S.A.
Inventors:
Sean D. McKenna, Robert K. Campbell, Xuliang Jiang, Giampiero De Luca, Meijia Yang, Christie Ann Kelton, Stephen J. Arkinstall, Chaomei He, Rene Lynn Schweickhardt
Abstract: The invention provides novel arylamino N-heteroaryl MEK inhibitors of Formula (I): Such compounds are MEK inhibitors that are useful in the treatment of hyperproliferative diseases, such as cancer and inflammation. Also disclosed is the treatment of a hyperproliferative disease in mammals, and pharmaceutical compositions containing such compounds.
Type:
Grant
Filed:
April 18, 2007
Date of Patent:
August 10, 2010
Assignee:
Merck Serono, S.A.
Inventors:
Andreas Goutopoulos, Benny C. Askew, Jr., Nhut Kiet Diep, Srinivasa Karra, Matthias Schwarz, Henry Yu
Abstract: The present invention is directed to compounds that may be used as agonists of prostaglandin receptors. More specifically, the specification describes methods and compositions for making and using DP1 receptor agonists that are pyrrolidin-2-one derivatives.
© 2024 Justia
